Inhibition of Akt/protein kinase B signaling by naltrindole in small cell lung cancer cells

Cancer Research

Volumn 64, Issue 23, 2004, Pages 8723-8730

  Chen, Yulong L ^a   Law, P Y ^a   Loh, Horace H ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOGEN SYNTHASE KINASE 3BETA; NALTRINDOLE; OPIATE ANTAGONIST; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOINOSITIDE DEPENDENT KINASE 1; PHOSPHOTRANSFERASE; PROTEIN KINASE B; SERINE; THREONINE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR AFX; TRANSCRIPTION FACTOR FKHR; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CELL SURVIVAL; CONTROLLED STUDY; DNA DETERMINATION; DNA MICROARRAY; DOWN REGULATION; DRUG SENSITIVITY; DRUG TARGETING; ENZYME PHOSPHORYLATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LUNG SMALL CELL CANCER; MICROSCOPY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

APOPTOSIS; BINDING SITES; CARCINOMA, SMALL CELL; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CELL SURVIVAL; GENE EXPRESSION; HUMANS; LUNG NEOPLASMS; NALTREXONE; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION;

EID: 9244256817     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-03-3091     Document Type: Article

References (45)

1. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J Clin 2003;53:5-26.
2. Cook RM, Miller YE, Bunn PA, Jr. Small cell lung cancer: etiology, biology, clinical features, staging, and treatment. Curr Probl Cancer 1993;17:69-141.
3. Salgia R, Skarin AT. Molecular abnormalities in lung cancer. J Clin Oncol 1998;16:1207-17.
4. Chang F, Lee JT, Navolanic PM, et al. Involvement of P13K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy. Leukemia 2003;17:590-603.
5. Kraus AC, Ferber I, Bachmann SO, et al. In vitro chemo- and radio-resistance in small cell lung cancer correlates with cell adhesion and constitutive activation of AKT and MAP kinase pathways. Oncogene 2002;21:8683-95.
6. Krystal GW, Sulanke G, Litz J. Inhibition of phosphatidylinositol 3-kinase-Akt signaling blocks growth, promotes apoptosis, and enhances sensitivity of small cell lung cancer cells to chemotherapy. Mol Cancer Ther 2002;1:913-22.
7. Brognard J, Clark AS, Ni Y, Dennis PA. Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res 2001;61:3986-97.
8. Galetic I, Andjelkovic M, Meier R, Brodbeck D, Park J, Hemmings BA. Mechanism of protein kinase B activation by insulin/insulin-like growth factor-I revealed by specific inhibitors of phosphoinositide 3-kinase-significance for diabetes and cancer. Pharmacol Ther 1999;82:409-25.
9. Bellacosa A, Testa JR, Staal SP, Tsichlis PN. A retroviral oncogene, akt, encoding a serine-threonine kinase containing an SH2-like region. Science (Wash DC) 1991;254:274-7.
10. Datta SR, Brunet A, Greenberg ME. Cellular survival: a play in three Akts. Genes Dev 1999;13:2905-27.
11. Brunet A, Bonni A, Zigmond MJ, et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 1999;96:857-68.
12. Alessi DR, Andjelkovic M, Caudwell B, et al. Mechanism of activation of protein kinase B by insulin and IGF-I. EMBO J 1996;15:6541-51.
13. Khwaja A. Akt is more than just a Bad kinase. Nature (Lond) 1999;401:33-4.
14. Vlahos CJ, Matter WF, Hui KY, Brown RF. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem 1994;269:5241-8.
15. Cantley LC. The phosphoinositide 3-kinase pathway. Science (Wash DC) 2002;296:1655-7.
16. Hill MM, Hemmings BA. Inhibition of protein kinase B/Akt. implications for cancer therapy. Pharmacol Ther 2002;93:243-51.
17. Portoghese PS, Sultana M, Takemori AE. Naltrindole, a highly selective and potent non-peptide delta opioid receptor antagonist. Eur Pharmacol 1988;146:185-6.
18. Arakawa K, Akami T, Okamoto M, Oka T, Nagase H, Matsumoto S. The immunosuppressive effect of delta-opioid receptor antagonist on rat renal allograft survival. Transplantation 1992;53:951-3.
19. Linner KM, Stickney BJ, Quist HE, Sharp BM, Portoghese PS. The delta1-opioid receptor antagonist, 7-(benzospiroindanyl)naltrexone [correction of 7-benzylspiroindanylnaltrexone], prolongs renal allograft survival in a rat model. Eur Pharmacol 1998;354:R3-5.
20. Carney DN, Gazdar AF, Bepler G, et al. Establishment and identification of small cell lung cancer cell lines having classic and variant features. Cancer Res 1985;45:2913-23.
21. Chen Y. Inhibition of K-ras-transformed rodent and human cancer cell growth via induction of apoptosis by irreversible inhibitors of Ras endoprotease. Cancer Lett 1998;131:191-200.
22. Roth KA, Barchas JD. Small cell carcinoma cell lines contain opioid peptides and receptors. Cancer (Phila) 1986;57:769-73.
23. Maneckjee R, Minna JD. Opioid and nicotine receptors affect growth regulation of human lung cancer cell lines. Proc Natl Acad Sci USA 1990;87:3294-8.
24. Campa MJ, Schreiber G, Bepler G, et al. Characterization of delta opioid receptors in lung cancer using a novel nonpeptidic ligand. Cancer Res 1996;56:1695-1701.
25. Davis TP, Burgess HS, Crowell S, Moody TW, Culling-Berglund A, Liu RH. Beta-endorphin and neurotensin stimulate in vitro clonal growth of human SCLC cells. Eur Pharmacol 1989;161:283-5.
26. Moore SM, Rintoul RC, Walker TR, Chilvers ER, Haslett C, Sethi T. The presence of a constitutively active phosphoinositide 3-kinase in small cell lung cancer cells mediates anchorage-independent proliferation via a protein kinase B and p70s6k-dependent pathway. Cancer Res 1998;58:5239-47.
27. Belham C, Wu S, Avruch J. Intracellular signalling: PDK1-a kinase at the hub of things. Curr Biol 1999;9:R93-96.
28. Prasad KV, Ao Z, Yoon Y, et al. CD27, a member of the tumor necrosis factor receptor family, induces apoptosis and binds to Siva, a proapoptotic protein. Proc Natl Acad Sci USA 1997;94:6346-51.
29. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature (Lond) 2001;411:494-8.
30. Peng XD, Xu PZ, Chen ML, et al. Dwarfism, impaired skin development, skeletal muscle atrophy, delayed bone development, and impeded adipogenesis in mice lacking Akt1 and Akt2. Genes Dev 2003;17:1352-65.
31. Maneckjee R, Minna JD. Opioids induce while nicotine suppresses apoptosis in human lung cancer cells. Cell Growth Differ 1994;5:1033-40.
32. Gupta K, Kshirsagar S, Chang L, et al. Morphine stimulates angiogenesis by activating proangiogenic and survival-promoting signaling and promotes breast tumor growth. Cancer Res 2002;62:4491-8.
33. Yuan J, Yankner BA. Apoptosis in the nervous system. Nature (Lond) 2000;407:802-9.
34. Wischhusen J, Jung G, Radovanovic I, et al. Identification of CD70-mediated apoptosis of immune effector cells as a novel immune escape pathway of human glioblastoma. Cancer Res 2002;62:2592-9.
35. Tian Q, Taupin J, Elledge S, Robertson M, Anderson P. Fas-activated serine/threonine kinase (FAST) phosphorylates TIA-I during Fas-mediated apoptosis. J Exp Med 1995;182:865-74.
36. Sladeczek F, Camonis JH, Burnol AF, Le Bouffant F. The Cdk-like protein PCTAIRE-1 from mouse brain associates with p11 and 14-3-3 proteins. Mol Gen Genet 1997;254:571-7.
37. Shao J, Sheng H, DuBois RN, Beauchamp RD. Oncogenic Ras-mediated cell growth arrest and apoptosis are associated with increased ubiquitin-dependent cyclin D1 degradation. J Biol Chem 2000l275:22916-24.
38. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (Wash DC) 2004;304:1497-500.
39. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
40. Sattler M, Salgia R. Molecular and cellular biology of small cell lung cancer. Semin Oncol 2003;30:57-71.
41. Seckl MJ, Higgins T, Widmer F, Rozengurt E. [D-Arg1,D-Trp5,7,9,Leu11] substance P: a novel potent inhibitor of signal transduction and growth in vitro and in vivo in small cell lung cancer cells. Cancer Res 1997;57:51-4.
42. Honore P, Luger NM, Sabino MA, et al. Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord. Nat Med 2000;6:521-8.
43. Patt RB, editor. Cancer pain. Philadelphia, PA: J.B. Lippincott Company; 1993. p. 1-650.
44. Zhu Y, King MA, Schuller AG. et al. Retention of supraspinal delta-like analgesia and loss of morphine tolerance in delta opioid receptor knockout mice. Neuron 1999;24:243-52.
45. Abdelhamid EE, Sultana M, Portoghese PS, Takemori AE. Selective blockage of delta opioid receptors prevents the development of morphine tolerance and dependence in mice. J Pharmacol Exp Ther 1991;258:299-303.